Crossmark

Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark

Crossref DOI link: https://doi.org/10.1007/s12325-019-00990-x

Published Online: 2019-06-01

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aksan, Ayşegül https://orcid.org/0000-0003-2819-3484
Dignass, Axel https://orcid.org/0000-0002-9724-054X
Stein, Jürgen https://orcid.org/0000-0003-3558-3341
Funding

Funding for this research was provided by:

Interdisciplinary Crohn-Colitis Center Rhein-Main, Germany
License Information

Text and Data Mining valid from 2019-06-01

Version of Record valid from 2019-06-01
More Information

Article History

Received: 13 March 2019

First Online: 1 June 2019